Assessing the impact of HBV NAT on window period reduction and residual risk
- 1 May 2006
- journal article
- review article
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S23-S29
- https://doi.org/10.1016/s1386-6532(06)80005-3
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or notTransfusion, 2005
- Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV testTransfusion, 2005
- Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donationsTransfusion, 2005
- International Forum: 1Vox Sanguinis, 2005
- Hepatitis B NAT virus‐positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNAVox Sanguinis, 2005
- Epidemiology of blood donors in Japan, positive for hepatitis B virus and hepatitis C virus by nucleic acid amplification testingVox Sanguinis, 2005
- Assessment of the Risk of Transfusion-Transmitted Viral InfectionsTransfusion Alternatives in Transfusion Medicine, 2003
- Trends in residual risk of transfusion‐transmitted viral infections in France between 1992 and 2000Transfusion, 2002
- NAT for HBV and anti‐HBc testing increase blood safetyTransfusion, 2002
- Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection.BMJ, 1993